I have been a shareholder in Amgen, the American biotech and pharmaceutical giant, for quite some time. If you look at the long-term stock price chart, you’ll see a positive trend—a slow but steady rise. Taken on its own, however, the last month looks like a disaster, even though the nearly 10% drop is more likely due to problems at competitors. $AMGN (+1,46%) In my opinion, Amgen was simply caught up in the turmoil.
Unfortunately, I don’t have any spare funds to invest further, and I’ve actually already reached my target allocation in my portfolio. I view Amgen as a long-term investment and, at the same time, as a reliable—albeit moderate—dividend payer. My personal dividend yield is just over 3%.
